Robert Preidt, an Ontario-based writer and photographer with 20 years’ newspaper and magazine experience; whose work has won numerous awards and appeared in the Toronto Star, the Medical Post and Family Practice magazine, recently released an article on HealthDay.com featuring a new type of blood test able to track the severity and spread of advanced melanoma at an earlier stage, making it significantly more effective than the current tests.
For expats living in the Yucatan Peninsula, skin cancer and melanoma are always a concern, due to high exposure to the sun rays people down here experience on a daily basis.
A new blood test might improve doctors’ ability to track the spread of advanced melanoma skin cancer, according to results of a small, preliminary study.
The test monitors blood levels of DNA fragments from dead cancer cells, and is more effective than the current test at tracking the severity and spread of advanced melanoma, the researchers said.
“Our study results show that circulating tumor DNA is a superior blood test for evaluating and tracking progression of metastatic melanoma,” study senior investigator Dr. David Polsky, from NYU Langone Medical Center in New York City, said in a center news release.
Currently, a test that measures blood levels of an enzyme called lactate dehydrogenase (LDH) is done to guide management of the cancer. LDH levels rise during aggressive tumor growth. However, levels of LDH also rise due to other diseases and biological functions, the study authors pointed out.
The new test assesses levels of circulating tumor DNA (ctDNA) released into the blood when tumor cells die, the researchers said.
The study included 31 patients with inoperable advanced (metastatic) melanoma who had both tests done.
The study found that blood levels of ctDNA were elevated in 80 percent of patients about to undergo treatment for the advanced melanoma. Blood levels of LDH were elevated in just 30 percent of such patients, the study showed.
Also, the ctDNA blood test detected cancer recurrence — confirmed by X-ray or CT scan — in 85 percent of patients tested and undergoing treatment. The LDH blood test detected 54 percent of such cases, the researchers said.
“Previous studies have suggested that ctDNA blood testing may also help monitor progression of breast and colon cancers”, Polsky, a dermatologist, said in the news release.
The new study findings are published in the January issue of the journal Molecular Oncology.
The U.S. National Cancer Institute has more about melanoma.
SOURCE: NYU Langone Medical Center, news release, Jan. 11, 2016
more recommended stories
Growth in tourism is expected in Valladolid during the summer holiday season
After carrying out various promotional activities,.
More employment opportunities in Yucatán
Yucatan registered a favorable 18% trend.
PROFEPA seizes wild animals in Motul, Yucatán
During an inspection visit in response.
In press release, CONAGUA discards versions of “water privatization” in Mexico
The ten Water Reserve Decrees published.
Campeche shows the highest growth in FDI at national level
Campeche was the entity that grew.
FIFA opened investigation against Mexico for “homophobic” behavior during World Cup
FIFA decided to open a disciplinary.
11 year-old girl will represent Yucatan at World Mathematics Olympiad in Bulgaria
To get to Molas you have.
Mérida attracts Chinese business sector attention
A delegation of the municipal government.
Yucatán national leader in avant garde technological solutions
Scientific staff will learn to market.
Fake photo brings out real issues
Social media users began circulating a.